Skip to main content

Advertisement

Correction to: Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells

The original article was published in BMC Cancer 2017 17:34

Correction to: BMC Cancer (2017) 17:34

https://doi.org/10.1186/s12885-016-3038-y

Following publication of the original article [1], the author noticed the following errors in the article.

1) The following authors were mistakenly omitted from the published article:

  1. a.

    Dr. Shile Huang as lead corresponding author

  2. b.

    Dr. Chao Zhang as co-author

The correct authorship is as follows:

Wenxing Chen1,2, Yanhong Pan1, Siliang Wang1, Yuping Liu1, Guangying Chen3, Liang Zhou1, Chao Zhang4, Wenting Ni1, Aiyun Wang1, Yin Lu1,2* and Shile Huang4*.

* Correspondence: shuan1@lsuhsc.edu and luyingreen@126.com

2) Correction to Acknowledgement statement. The correct statement is as follows:

This work was supported in part by Natural Science Foundation of Jiangsu Province (BK2012854, W. Chen), National Natural Science Foundation of China (81673648, W. Chen;81173174, Y. Lu; 21162009, G. Chen), the National Institutes of Health NCI CA115414, S. Huang), American Cancer Society (RSG-08-135-01-CNE, S. Huang), Feist- Weiller Cancer Center, Louisiana State University Health Sciences Center, and a project of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Qing Lan Project of Jiangsu and a preliminary foundation of NJUCM (13XYYZ4).

3) Correction to Authors’ contribution statement. The correct statement is as follows:

WXC, YL, and SH conceived the project and designed the research. WXC performed adenoviral and lentiviral assays, and YHP, YPL, WTN, and CZ conducted cell culture and western blot. SLW conducted the molecular docking. LZ prepared the figures and performed the statistical analysis. AYW, GYC, and YL participated in coordination. WXC wrote the manuscript. All authors read and approved the final manuscript.

4) Figure correction: The authors noticed an error in Fig. 8a. Please see the correct Fig. 8a and figure legend below.

Fig. 8
figure1

Activation of TSC2 involved in CPT inhibition of mTORC1 signaling. a Rh30 and DU145 cells were exposed to CPT (0–20 μmol/L) for 24 h, followed by western blotting with indicated antibodies

The authors apologize for any inconvenience caused.

Reference

  1. 1.

    Chen W, et al. Cryptotanshinone activates AMPK-TSC2 axis leading to inhibition of mTORC1 signaling in cancer cells. BMC Cancer. 2017;17:34. https://doi.org/10.1186/s12885-016-3038-y.

Download references

Author information

Correspondence to Yin Lu or Shile Huang.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark